Key terms
About CODX
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CODX news
Apr 04
9:32am ET
Co-Diagnostics appoints Richard Abbott as president
Mar 21
9:35am ET
Co-Diagnostics CEO Dwight Egan delivers manufacturing, commercialization update
Mar 15
4:24pm ET
Co-Diagnostics Inc Welcomes Richard Abbott as New President
Mar 15
6:12am ET
Co-Diagnostics price target lowered to $2.50 from $3 at H.C. Wainwright
Mar 14
4:03pm ET
Co-Diagnostics reports cash, equivalents of $58.5M as of December 31, 2023
Mar 11
8:00am ET
Options Volatility and Implied Earnings Moves This Week, March 11 – March 15, 2024
Mar 07
9:32am ET
Co-Diagnostics JV cleared by CDSCO to sell Influenza Multiplex PCR Test
No recent news articles are available for CODX
No recent press releases are available for CODX
CODX Financials
Key terms
Ad Feedback
CODX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CODX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
